Tampa, FL Clinical Trials Report — May 2026

For Tampa residents interested in contributing to medical research, May 2026 brings both immediate opportunities and new avenues for participation. A significant number of clinical trials are nearing their enrollment deadlines, making prompt action essential for those considering joining a study.

A total of 79 clinical trials in Tampa are scheduled to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 6 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

New Research Opportunities in Tampa

This month, Tampa saw the opening of 9 new clinical trials, a decrease from the 12 trials that launched in April 2026. Despite this dip, the city continues to offer a robust research landscape with 1,024 clinical trials currently recruiting across 421 research facilities.

May brings several notable new trials to Tampa, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges:

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• Eli Lilly and Company is sponsoring two significant trials. NCT07602582, "A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT)," is a Phase 3 study involving 550 participants to determine if annual doses of donanemab provide clinical benefit to those who previously took the drug. Their second trial, NCT07589595, "A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)," is a Phase 2 study with 350 participants, evaluating whether donanemab slows the progression of cognitive and functional decline.
• The Canopy Cancer Collective, LLC is leading NCT07605702, "The Canopy Cancer Collective Clinical Registry Protocol," a large observational registry protocol aiming for 100,000 participants to systematically collect comprehensive data on gastrointestinal cancer patients.
• Apollo Therapeutics Ltd is sponsoring NCT07599813, "A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis," a randomized, double-blind, placebo-controlled study with 280 participants.
• Definium Therapeutics US, Inc. is behind NCT07592689, "A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)," a double-blind, placebo-controlled study with 165 participants.

New trials this month are exploring a range of conditions, with the most frequent being Alzheimer disease, amyloid, atopic dermatitis, cognitive dysfunction, colorectal cancer, and dementia, each with 1 new trial. Drug trials account for the largest share of new studies, with 6 new drug trials, followed by 1 device trial, 1 other type of study, and 1 procedure trial. Industry sponsors are driving the majority of new research, with 7 new trials sponsored by industry, 1 by a network, and 1 by another type of sponsor.

Leading Research Facilities in Tampa

Tampa is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Moffitt Cancer Center (282 trials)
• University of South Florida (108 trials)
• Tampa General Hospital (64 trials)
• Saint Joseph's Hospital/Children's Hospital-Tampa (40 trials)
• Research Site (34 trials)
• Moffitt Cancer Center - McKinley Campus (27 trials)
• Moffitt Cancer Center-International Plaza (24 trials)

These institutions offer a broad spectrum of research, with Moffitt Cancer Center specializing in oncology, and the University of South Florida and Tampa General Hospital covering diverse medical fields.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Myasthenia gravis (3 trials)
• Pancreatic cancer (2 trials)
• Cancer (2 trials)
• Melanoma stage iii (2 trials)
• Systemic lupus erythematosus (2 trials)
• Renal impairment (2 trials)
• Depressive disorder, major (2 trials)
• Cholangiocarcinoma (2 trials)
• Ovarian cancer (2 trials)
• Melanoma stage iv (2 trials)

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 9 new trials launched this month, 1 is actively seeking healthy volunteers. Across Tampa, a total of 56 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Broadening Your Search: Nearby Options

While Tampa offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Florida. Cities with active trials include Miami (23 trials), Jacksonville (12 trials), Orlando (9 trials), Gainesville (6 trials), Winter Park (6 trials), Maitland (5 trials), Miami Lakes (4 trials), and Coral Gables (4 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 9 new trials launched this month, all include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is male-only, while none are specifically for children or female-only. As Tampa continues to be a hub for medical innovation, new opportunities for participation are always on the horizon.